Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Southern California
Headquarters: Los Angeles, CA, United States of America
Website: http://www.usc.edu
Year Founded: 1880
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Sep 19, 2024
Discovery & Translation
A multisite preclinical study brings rigor to stroke research. Is the model generalizable?
High-quality, reproducible preclinical science is feasible, says USC Keck School’s Patrick Lyden: a BioCentury Q&A
BioCentury | Mar 12, 2024
Discovery & Translation
Distillery spotlight: new mitochondrial mechanisms from academia
Correcting mitochondrial dynamics, metabolic control of pathogenic or therapeutic cells emerge among translational innovations in BioCentury’s survey of 2023 publications
BioCentury | Dec 15, 2023
Discovery & Translation
GDF15 linked to severe nausea in pregnancy; plus Carvykti mechanism and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 12, 2023
Distillery Therapeutics
Inhibiting ORAI calcium channels for airway hyperactivity
BioCentury | Oct 6, 2023
Discovery & Translation
An AbbVie-Calico cancer therapy; plus Moderna’s monkeypox vaccine and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 6, 2023
Market Access
New cost-effectiveness model aims to better capture value of medicines to society
No Patient Left Behind’s updated methodology accounts for disease severity, loss of market exclusivity and social value
BioCentury | May 8, 2023
Politics, Policy & Law
House Republicans amping criticism of Biden’s drug access policies
Hearing Wednesday will address Alzheimer’s access, Inflation Reduction Act, other policies GOP says limit access and inhibit innovation
BioCentury | Apr 26, 2023
Politics, Policy & Law
Industry asks CMS to drop cost-plus approach to IRA
Other stakeholders comment on rewarding RWE, criteria for orphan exemption, alternatives to QALYs, and more
Items per page:
1 - 10 of 222